BRPI0416916A - promotores para expressão em vìrus de vacìnia modificada ankara - Google Patents

promotores para expressão em vìrus de vacìnia modificada ankara

Info

Publication number
BRPI0416916A
BRPI0416916A BRPI0416916-6A BRPI0416916A BRPI0416916A BR PI0416916 A BRPI0416916 A BR PI0416916A BR PI0416916 A BRPI0416916 A BR PI0416916A BR PI0416916 A BRPI0416916 A BR PI0416916A
Authority
BR
Brazil
Prior art keywords
expression
promoters
vaccinia virus
modified vaccinia
virus ankara
Prior art date
Application number
BRPI0416916-6A
Other languages
English (en)
Inventor
Sonja Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of BRPI0416916A publication Critical patent/BRPI0416916A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"PROMOTORES PARA EXPRESSãO EM VìRUS DE VACìNIA MODIFICADA ANKARA". A presente invenção refere-se promotores, em particular para a expressão de genes e/ou seqüências de codificação em vírus de vacínia tal como vírus de vacínia modificada Ankara (MVA). A invenção ulteriormente refere-se a cassetes de expressão compreendendo o dito promotor, vetores compreendendo os ditos cassetes de expressão bem como composição farmacêuticas e vacinas.
BRPI0416916-6A 2003-11-24 2004-10-27 promotores para expressão em vìrus de vacìnia modificada ankara BRPI0416916A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301730 2003-11-24
EP04000943A EP1536015B1 (en) 2003-11-24 2004-01-17 Promoters for expression in modified vaccinia virus ankara
PCT/EP2004/012125 WO2005054484A1 (en) 2003-11-24 2004-10-27 Promoters for expression in modified vaccinia virus ankara

Publications (1)

Publication Number Publication Date
BRPI0416916A true BRPI0416916A (pt) 2007-01-23

Family

ID=34442836

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416916-6A BRPI0416916A (pt) 2003-11-24 2004-10-27 promotores para expressão em vìrus de vacìnia modificada ankara

Country Status (18)

Country Link
US (3) US7816508B2 (pt)
EP (4) EP1536015B1 (pt)
JP (2) JP2007512009A (pt)
KR (1) KR20060109873A (pt)
CN (1) CN1898390A (pt)
AT (4) ATE471383T1 (pt)
AU (1) AU2004295382A1 (pt)
BR (1) BRPI0416916A (pt)
CA (1) CA2546680A1 (pt)
DE (4) DE602004027767D1 (pt)
DK (3) DK1536015T3 (pt)
EA (1) EA012846B1 (pt)
IL (4) IL174653A0 (pt)
NO (1) NO20062948L (pt)
NZ (1) NZ547405A (pt)
SG (2) SG169325A1 (pt)
UA (1) UA90098C2 (pt)
WO (1) WO2005054484A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042480A2 (en) * 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
ATE471383T1 (de) * 2003-11-24 2010-07-15 Bavarian Nordic As Promotoren zur expression in modifiziertem vaccinia virus ankara
EP2042604A1 (en) * 2007-09-26 2009-04-01 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) VV promoter driven overexpression of recombinant antigens
JP2012509678A (ja) * 2008-11-27 2012-04-26 バヴァリアン・ノルディック・アクティーゼルスカブ 組換えウイルス発現のためのプロモーター
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
AU2011316164B2 (en) 2010-10-15 2016-01-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106754921A (zh) * 2016-12-12 2017-05-31 孙浩 哺乳动物细胞表达启动子及其制造和使用方法
EP3621646A4 (en) * 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
CN121443308A (zh) 2023-03-17 2026-01-30 亥姆霍兹慕尼黑中心-德国健康与环境研究中心(有限公司) 用于治疗乙型肝炎的hbv抗原制剂
WO2025172435A1 (en) 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
WO2002072754A2 (en) * 2001-03-08 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva expressing modified hiv envelope, gag, and pol genes
MXPA02008873A (es) 2000-03-14 2003-02-10 Anton Mayr Cepa alterada del virus de vaccinia ankara modificado (mva).
WO2002042480A2 (en) * 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
BR0310020A (pt) 2002-05-16 2005-02-15 Bavarian Nordic As Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
EP2264178A1 (en) * 2002-08-07 2010-12-22 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of Avipoxviruses
ATE471383T1 (de) * 2003-11-24 2010-07-15 Bavarian Nordic As Promotoren zur expression in modifiziertem vaccinia virus ankara

Also Published As

Publication number Publication date
DE602004018975D1 (de) 2009-02-26
IL199127A (en) 2010-12-30
EP1845164B1 (en) 2010-06-16
EA200601043A1 (ru) 2006-10-27
DE602004009743T2 (de) 2008-08-28
EP1956094A1 (en) 2008-08-13
IL199128A (en) 2011-03-31
JP2011067219A (ja) 2011-04-07
CN1898390A (zh) 2007-01-17
US20080112971A1 (en) 2008-05-15
DE602004032187D1 (de) 2011-05-19
EP1536015A1 (en) 2005-06-01
ATE504654T1 (de) 2011-04-15
US20110008792A1 (en) 2011-01-13
NO20062948L (no) 2006-08-23
UA90098C2 (en) 2010-04-12
EP1956094B1 (en) 2011-04-06
DE602004009743D1 (de) 2007-12-13
ATE471383T1 (de) 2010-07-15
JP2007512009A (ja) 2007-05-17
US20110014242A1 (en) 2011-01-20
EP1845164A2 (en) 2007-10-17
CA2546680A1 (en) 2005-06-16
IL174653A0 (en) 2006-08-20
DK1845164T3 (da) 2010-09-20
SG169325A1 (en) 2011-03-30
US7816508B2 (en) 2010-10-19
KR20060109873A (ko) 2006-10-23
EP1689872A1 (en) 2006-08-16
EA012846B1 (ru) 2009-12-30
EP1845164A3 (en) 2008-03-19
WO2005054484A1 (en) 2005-06-16
SG142300A1 (en) 2008-05-28
IL199126A (en) 2010-12-30
ATE377088T1 (de) 2007-11-15
ATE420191T1 (de) 2009-01-15
DK1689872T3 (da) 2009-04-27
EP1689872B1 (en) 2009-01-07
AU2004295382A1 (en) 2005-06-16
NZ547405A (en) 2008-06-30
DE602004027767D1 (de) 2010-07-29
EP1536015B1 (en) 2007-10-31
DK1536015T3 (da) 2008-02-18

Similar Documents

Publication Publication Date Title
BRPI0416916A (pt) promotores para expressão em vìrus de vacìnia modificada ankara
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2004096993A3 (en) Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
NO20090780L (no) Human Glp-1 mimetistoff, sammensetninger, fremgangsmater og anvendelser
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
BRPI0512421A (pt) recombinantes de avipox expressando genes do vìrus da doença febre aftosa
DE60302848D1 (de) Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter
BR0209551A (pt) Promotor de gene especìfico de folha de café
PE20121171A1 (es) Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos
MX2022015489A (es) Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
CY1107186T1 (el) Προαγωγος πολυμερασης i rna κοτοπουλου και η χρηση αυτου
NO20081541L (no) Ny sjo-lus vaksine
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
DK1554383T3 (da) Rekombinante MVA-stammer som potentieller vacciner mod P. falciparum-malaria
NO20085201L (no) Rekombinante novirhabdoviruser og deres anvendelse
BR0308180A (pt) protéinas de superfìcie de leptospira
ATE547530T1 (de) Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase
BR0316553A (pt) Poxvìrus recombinante que compreende pelo menos dois promotores ati de varìola bovina
HK1181677A (en) Ectodomains of influenza matrix 2 protein, expression system, and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]